November 12, 2018 08:31 AM EST
R&D

No­var­tis builds block­buster case for En­tresto, beat­ing out a cheap ACE in­hibitor — or not

John Carroll

Editor & Founder

No­var­tis ex­ecs got the pos­i­tive da­ta they were look­ing for from their PI­O­NEER-HF study of En­tresto to back ac­cel­er­at­ing sales of the heart med­ica­tion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times